{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:23:29Z","timestamp":1769127809889,"version":"3.49.0"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>Tuberculosis (TB) is a major global health issue, with approximately 10 million people being infected each year, and is the leading cause of mortality from infectious disease, with 1.5 million deaths a year. Optimal TB treatment requires a combination of drugs for an adequate treatment duration owing to persistent organisms, hardly accessible infection sites, and a high risk of resistance selection. Long-term therapy increases the risk of patients' loss of adherence, adverse drug reactions, and drug\u2013drug interactions, potentially leading to treatment failure. The high interpatient variability of TB drug exposure is another point eliciting interest in therapeutic drug monitoring (TDM) to optimize treatment. Studies reporting clinically relevant exposure thresholds, which might be proposed as targets toward treatment personalization, are discussed. Practical TDM strategies have also been reported to circumvent issues related to delayed drug absorption and the need for multiple samples when evaluating the area under the curve of drug concentrations. The need for treatment individualization is further emphasized because of the development of multidrug-resistant TB or extensively drug-resistant TB. Finally, the willingness to shorten the treatment duration while maintaining success is also a driver for ensuring adequate exposure to TB drugs with TDM. The aim of the present review was to underline the role of TDM in drug-susceptible TB and World Health Organization group A TB drugs.<\/jats:p>","DOI":"10.1097\/ftd.0000000000000948","type":"journal-article","created":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T02:16:52Z","timestamp":1638497812000},"page":"133-137","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Has the Time Come for Systematic Therapeutic Drug Monitoring of First-Line and WHO Group A Antituberculosis Drugs?"],"prefix":"10.1097","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0908-3629","authenticated-orcid":false,"given":"Florian","family":"Lemaitre","sequence":"first","affiliation":[{"name":"Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en sant\u00e9, environnement et travail); and"},{"name":"Univ Rennes, CHU Rennes, Inserm, CIC 1414 (Centre d'Investigation Clinique de Rennes), Rennes, France."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/S0140-6736(19)30308-3","article-title":"Tuberculosis","volume":"393","author":"Furin","year":"2019","journal-title":"Lancet"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1128\/AAC.50.4.1170-1177.2006","article-title":"Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients","volume":"50","author":"McIlleron","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(16)30274-2","article-title":"High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial","volume":"17","author":"Boeree","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s40262-019-00764-2","article-title":"Clinical pharmacokinetics and pharmacodynamics of rifampicin in human tuberculosis","volume":"58","author":"Abulfathi","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00228-016-2132-z","article-title":"Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus","volume":"73","author":"Kumar","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1128\/AAC.47.7.2118-2124.2003","article-title":"Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis","volume":"47","author":"Jayaram","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1128\/AAC.01533-06","article-title":"Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin","volume":"51","author":"Gumbo","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s40265-014-0222-8","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis: an update","volume":"74","author":"Alsultan","year":"2014","journal-title":"Drugs"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/joim.12780","article-title":"Perspectives for personalized therapy for patients with multidrug-resistant tuberculosis","volume":"284","author":"Lange","year":"2018","journal-title":"J Intern Med"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/j.tube.2019.04.012","article-title":"Pharmacokinetics of isoniazid: the good, the bad, and the alternatives","volume":"116S","author":"Erwin","year":"2019","journal-title":"Tuberculosis (Edinb)"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/bcp.12885","article-title":"Mechanism of isoniazid-induced hepatotoxicity: then and now","volume":"81","author":"Metushi","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s00228-012-1429-9","article-title":"NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy","volume":"69","author":"Azuma","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1128\/AAC.00185-07","article-title":"Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations","volume":"51","author":"Gumbo","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1086\/599040","article-title":"Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana","volume":"48","author":"Chideya","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1128\/AAC.01681-08","article-title":"Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs","volume":"53","author":"Gumbo","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R17-20250603","first-page":"1360","article-title":"Pharmacokinetics of ethambutol in children and adults with tuberculosis","volume":"8","author":"Zhu","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1093\/cid\/ciz942","article-title":"Integrating pharmacokinetics and pharmacodynamics in operational research to end tuberculosis","volume":"70","author":"Alffenaar","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R19-20250603","first-page":"967","article-title":"Ethambutol-induced optical neuropathy: risk of overdosing in obese subjects","volume":"12","author":"Hasenbosch","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1183\/09031936.00176610","article-title":"Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience","volume":"38","author":"Pranger","year":"2011","journal-title":"Eur Respir J"},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"S293","DOI":"10.1093\/cid\/ciy611","article-title":"Levofloxacin pharmacokinetics\/pharmacodynamics, dosing, susceptibility breakpoints, and artificial intelligence in the treatment of multidrug-resistant tuberculosis","volume":"67","author":"Deshpande","year":"2018","journal-title":"Clin Infect Dis"},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijantimicag.2018.10.012","article-title":"Dose optimization of moxifloxacin and linezolid against tuberculosis using mathematical modeling and simulation","volume":"53","author":"Heinrichs","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"e00279-19","DOI":"10.1128\/AAC.00279-19","article-title":"Fluoroquinolones in drug-resistant tuberculosis: culture conversion and pharmacokinetic\/pharmacodynamic target attainment to guide dose selection","volume":"63","author":"Al-Shaer","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1517\/14740338.2013.796362","article-title":"Risks associated with the therapeutic use of fluoroquinolones","volume":"12","author":"Stahlmann","year":"2013","journal-title":"Expert Opin Drug Saf"},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1517\/14656566.2015.1080240","article-title":"Bedaquiline and delamanid in tuberculosis","volume":"16","author":"Esposito","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1093\/jac\/dkx317","article-title":"Modelling of mycobacterial load reveals bedaquiline's exposure-response relationship in patients with drug-resistant TB","volume":"72","author":"Svensson","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"e00751-17","DOI":"10.1128\/AAC.00751-17","article-title":"Linezolid dose that maximizes sterilizing effect while minimizing toxicity and resistance emergence for tuberculosis","volume":"61","author":"Srivastava","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"819","DOI":"10.5588\/ijtld.15.0803","article-title":"Therapeutic drug monitoring in anti-tuberculosis treatment: a systematic review and meta-analysis","volume":"20","author":"Mota","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"e00038-17","DOI":"10.1128\/AAC.00038-17","article-title":"Pharmacokinetic evidence from the HIRIF trial to support increased doses of rifampin for tuberculosis","volume":"61","author":"Peloquin","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1086\/498024","article-title":"The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis","volume":"41","author":"Perlman","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1164\/rccm.201712-2524OC","article-title":"Efficacy and safety of high-dose rifampin in pulmonary tuberculosis. A randomized controlled trial","volume":"198","author":"Vel\u00e1squez","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1164\/rccm.200208-951OC","article-title":"Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine","volume":"167","author":"Weiner","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/infdis\/jit352","article-title":"Serum drug concentrations predictive of pulmonary tuberculosis outcomes","volume":"208","author":"Pasipanodya","year":"2013","journal-title":"J Infect Dis"},{"key":"R34-20250603","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/cid\/ciy179","article-title":"Delayed sputum culture conversion in tuberculosis-human immunodeficiency virus-coinfected patients with low isoniazid and rifampicin concentrations","volume":"67","author":"Sekaggya-Wiltshire","year":"2018","journal-title":"Clin Infect Dis"},{"key":"R35-20250603","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1056\/NEJMoa1201964","article-title":"Linezolid for treatment of chronic extensively drug-resistant tuberculosis","volume":"367","author":"Lee","year":"2012","journal-title":"N Engl J Med"},{"key":"R36-20250603","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ijantimicag.2014.12.027","article-title":"Pharmacokinetic\/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis","volume":"45","author":"Te Brake","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"R37-20250603","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s40262-020-00971-2","article-title":"A model-informed method for the purpose of precision dosing of isoniazid in pulmonary tuberculosis","volume":"60","author":"van Beek","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"R38-20250603","doi-asserted-by":"crossref","first-page":"e00384-19","DOI":"10.1128\/AAC.00384-19","article-title":"Limited sampling strategies using linear regression and the Bayesian approach for therapeutic drug monitoring of moxifloxacin in tuberculosis patients","volume":"63","author":"van den Elsen","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R39-20250603","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1097\/FTD.0000000000000093","article-title":"Limited sampling strategies to predict the area under the concentration-time curve for rifampicin","volume":"36","author":"Medell\u00edn-Garibay","year":"2014","journal-title":"Ther Drug Monit"},{"key":"R40-20250603","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/FTD.0b013e31821b793c","article-title":"Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis","volume":"33","author":"Pranger","year":"2011","journal-title":"Ther Drug Monit"},{"key":"R41-20250603","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/FTD.0b013e3181cc6d6f","article-title":"Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis","volume":"32","author":"Alffenaar","year":"2010","journal-title":"Ther Drug Monit"},{"key":"R42-20250603","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ijantimicag.2014.04.019","article-title":"Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin","volume":"44","author":"Magis-Escurra","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"R43-20250603","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1128\/AAC.00341-15","article-title":"Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis","volume":"59","author":"Alsultan","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R44-20250603","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s40262-019-00763-3","article-title":"Optimal sampling strategies for therapeutic drug monitoring of first-line tuberculosis drugs in patients with tuberculosis","volume":"58","author":"Saktiawati","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"R45-20250603","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.2174\/138161211797470174","article-title":"Dried blood spots: a new tool for tuberculosis treatment optimization","volume":"17","author":"Vu","year":"2011","journal-title":"Curr Pharm Des"},{"key":"R46-20250603","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/FTD.0000000000000462","article-title":"Systematic review of salivary versus blood concentrations of antituberculosis drugs and their potential for salivary therapeutic drug monitoring","volume":"40","author":"van den Elsen","year":"2018","journal-title":"Ther Drug Monit"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000948","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:29:08Z","timestamp":1748971748000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000948","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"2021-08-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}